PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 1, 2022Journal of Orthopaedic TranslationOpen Access

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Identifying new therapeutic targets for osteoarthritis is urgent because there is currently no disease-modifying therapy available.

Do GLP-1 analogues have potential as disease-modifying osteoarthritis drugs (DMOADs) in people suffering from OA?

Design

Review

Authors

CMC. MeurotCJC. JacquesCMC. Martin

Discussion

Loading...

Member takes

Overview

Caution against routine OA use; leaves open GLP-1 analogues as DMOADs pending trials.

Structured PICO

Do GLP-1 analogues have potential as disease-modifying osteoarthritis drugs (DMOADs) in people suffering from OA?

P
Population
People suffering from osteoarthritis (OA)
I
Intervention
GLP-1 analogues
O
Outcome
Disease modification (potential as DMOADs)

GLP-1 analogues represent a potential new therapeutic opportunity as disease-modifying drugs for osteoarthritis.

Cite This Study

Meurot et al. (2022) studied this question.

synapsesocial.com/papers/69d9fff40f32475823a3cb63https://doi.org/10.1016/j.jot.2022.02.001
View Full Paper
Ask AI
Bookmark
Share